| 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. | |
| | |
MedLine Citation:
|
PMID: 9869167 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A deletion/insertion polymorphism (4G or 5G) in the promoter of the plasminogen activator inhibitor type 1 gene has been suggested to be involved in regulation of the synthesis of the inhibitor, the 4G allele being associated with enhanced gene expression. A relationship between 4G/5G polymorphism and PAI-1 levels was found in patients with cardiovascular and metabolic diseases, but not in healthy subjects. In the present work we studied the distribution of PAI-1 4G/5G genotype and its relation to fibrinolytic capacity in 70 unrelated patients with deep vein thrombosis. Each patient was assayed before and after 20 min. Venous occlusion for euglobulin lysis time, t-PA antigen and activity, and PAI-1 antigen and activity. The prevalence of 5G homozygous carriers was significantly lower in patients than in controls (10% vs. 26%, p=0.009). The 5G allele frequency was reduced, even though not significantly, in DVT patients compared to healthy subjects (0.40 vs. 0.51, respectively). In the patient group, the mean PAI-1 antigen and activity levels were significantly higher than among controls and related to the 4G/5G polymorphism. In patients with 4G/5G and 4G/4G genotype a significant correlation was found between PAI-1 levels and the global fibrinolytic activity as evaluated by euglobulin lysis time. The prevalence of a reduced fibrinolytic potential due to PAI-1 excess was 45.7% among DVT patients. Moreover, the prevalence of PAI-1 induced hypofibrinolysis was strongly related to PAI-1 polymorphism, since it was significantly lower in 5G homozygous patients (28.6%) than in both 4G/5G carriers (55.3%, p <0.001) and 4G homozygous patients (57.9%, p <0.001). In conclusion, in patients with deep vein thrombosis the 4G polymorphism of PAI-1 gene promoter may influence the expression of PAI-1 and it should be taken into consideration as a facilitating condition for pathological fibrinolysis together with other environmental and genetic factors. Whether this has any significance in regard to the pathogenesis of venous thrombosis remains to be proven. |
| | |
Authors:
|
M T Sartori; B Wiman; S Vettore; F Dazzi; A Girolami; G M Patrassi |
Related Documents
:
|
16689757 - Accuracy of clinical decision rule, d-dimer and spiral computed tomography in patients ... 3042817 - Lipomembranous changes in chronic panniculitis. 18080727 - Incidence of lower limbs deep vein thrombosis after open and laparoscopic gastric bypas... 7849157 - Fatal pulmonary embolism in an unselected series: the possible role of caval filters in... 9455667 - Disc degeneration in young patients with isthmic spondylolisthesis treated operatively ... 22982937 - A retrospective review of diabetic nephropathy patients during referral to the sub-urba... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 80 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 1998 Dec |
Date Detail:
|
Created Date: 1999-04-15 Completed Date: 1999-04-15 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 956-60 Citation Subset: IM |
Affiliation:
|
Institute of Medical Semeiotics, II Chair of Internal Medicine, University of Padua Medical School, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Alleles Blood Coagulation Tests Female Fibrinolysis / genetics* Gene Expression Regulation Gene Frequency Genetic Predisposition to Disease Genotype Humans Male Middle Aged Mutagenesis, Insertional Plasminogen Activator Inhibitor 1 / genetics* Polymorphism, Genetic* Promoter Regions, Genetic / genetics* Sequence Deletion Thrombophilia / genetics Thrombophlebitis / blood, genetics* Tissue Plasminogen Activator / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Plasminogen Activator Inhibitor 1; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms.
Next Document: Evidence for the expression of urokinase-type plasminogen activator by human venous endothelial cell...